Warning: fopen(/home/virtual/pediatrics/journal/upload/ip_log/ip_log_2025-08.txt) [function.fopen]: failed to open stream: Permission denied in /home/virtual/pediatrics/journal/ip_info/view_data.php on line 93

Warning: fwrite(): supplied argument is not a valid stream resource in /home/virtual/pediatrics/journal/ip_info/view_data.php on line 94
Myopia: a review of current concepts, association with nonophthalmological conditions, and treatment strategy in children and adolescents

Volume 68(8); August

< Previous     Next >

Article Contents

Clin Exp Pediatr > Volume 68(8); 2025
Chung: Myopia: a review of current concepts, association with nonophthalmological conditions, and treatment strategy in children and adolescents

Abstract

Myopia, among the most common vision disorders worldwide, is projected to affect approximately 50% of the world's population by 2050. Its prevalence is particularly high in East Asia, posing a considerable public health challenge. In particular, high myopia, defined as ≤−6.0 diopters, significantly increases an individual's lifetime risk of vision-threatening complications. Moreover, recent studies revealed that nonophthalmological factors such as body stature, sleep patterns, and nutritional status are strongly correlated with the progression of myopia, particularly in childhood and adolescence, underscoring the need for a systemic approach to its control. Current therapeutic approaches include optical correction, pharmacological treatment, and increased outdoor activity. Optically, defocus-incorporated multisegment spectacle lenses and orthokeratology have shown efficacy at controlling the progression of myopia through peripheral retinal defocus and corneal reshaping, respectively. Pharmacologically, atropine eye drops, especially at low concentrations (0.05%), have demonstrated efficacy at myopia control with minimal side effects, making them a preferred treatment option for progressive myopia. Behaviorally, increased outdoor activity (minimum 2 hours daily) and decreased excessive near work, particularly on digital devices, can help prevent the progression of myopia. Furthermore, studies have aimed to prevent the progression from premyopia to myopia.

Introduction

Myopia is among the most prevalent ophthalmological disorders worldwide, with a rapid increase in prevalence occurring in East Asia. Moreover, Holden et al. estimated that approximately 49.8% of the global population will be affected by myopia by 2050 [1].
Myopia is a refractive error in which the light entering the eye focuses in front of the retina. In myopia, the spherical equivalent refractive error of the eye is ≤–0.5 diopters (D) under relaxed ocular accommodation [2]. Based on severity, it is classified as pre-, low, or high myopia (Table 1). This condition primarily results from excessive axial elongation [2-4], and its development involves complex interactions between genetic and environmental factors [5-8].
Studies have shown that myopia significantly affects quality of life and influences academic performance, career options, and daily activities [9]. Consequently, controlling its progression has become increasingly important for mitigating such complications.
Recent studies have identified a trend toward an earlier onset of myopia attributed to the increased use of digital devices and decreased outdoor activity [10-12]. Considering these challenges, preventing and managing its progression have emerged as crucial modern healthcare challenges. Managing myopia in children and adolescents is particularly important because it is directly correlated with adulthood visual health. Therefore, its early detection and timely intervention are essential. This study aimed to systematically review the epidemiology, mechanisms, and pathophysiology of myopia as well as its associations with extraocular conditions and strategies for its treatment and prevention.

Importance of myopia in ophthalmology

Myopia involves more than simple visual impairment, as it carries various ophthalmological risks. High myopia, defined as ≤6.0 D, significantly increases an individual's risk of several serious eye diseases [13-16]. This occurs because the eyeball elongates anteroposteriorly in myopia, causing the retina to thin and stretch and making it vulnerable to various pathological changes [17].
Retinal detachment is among the most serious complications of myopia. According to several studies, patients with high myopia are at higher risk of retinal detachment than those with normal vision [18,19]. If retinal detachment is not treated early, blindness may occur in more than 90% of cases; even with timely surgery, approximately 10% of patients experience permanent vision loss [20].
Myopic traction maculopathy is a progressive disease that begins with inner macular schisis in the innermost layer of the retina [21]. It then gradually progresses to involve the outer retinal layers, eventually leading to macular detachment as the schisis resolves. This condition affects approximately 30% of high-myopia eyes, causing various clinical manifestations in the macula, including separation, detachment, and the formation of holes, resulting from retinal modifications. Approximately 50% of patients with myopic traction maculopathy experience significant visual deterioration, such as full-thickness macular holes or macular detachment, within 2 years [22].
Increased axial elongation in high myopia may lead to mechanical stretching and thinning of the choroid and retinal pigment epithelium along with concomitant vascular and degenerative changes [23]. These abnormalities include retinal breaks, chorioretinal atrophy, Fuchs' spots, lacquer cracks, pigmentary degeneration, lattice degeneration, posterior staphyloma, and chorioretinal neovascularization, which may result in long-term visual deterioration and distortion [24].
Heavy eye syndrome is characterized by progressive, usually large-angle, esotropia and hypotropia leading to restricted abduction and supraduction. This condition is an acquired progressive strabismus commonly observed in eyes with increased axial length and high myopia [25-27]. Elongation of the myopic globe causes herniation between the superior rectus and lateral rectus muscles that displaces the former medially and latter inferiorly. Patients with high myopia often report progressive diplopia, eye strain, and associated headaches in the context of high myopia [26]. Furthermore, reports indicate that moderate myopia can also lead to conditions that may affect vision, including white dot syndrome [28], dome-shaped maculopathy [29], and glaucomatous optic disc tilting [30].
The increasing demand for refractive surgery, such as laser-assisted subepithelial keratectomy and laser-assisted in situ keratomileusis, also contributes to socioeconomic burden and potential surgical complications including corneal ectasia and opacity. According to a cost study of myopia-related healthcare utilization and the economic burden in urban China, the financial impact is substantial. The annual expense for myopia treatment (including spectacles, orthokeratology, and refractive laser surgery) and prevention amounts to $10.1 billion ($69 per person), while productivity losses total $6.7 billion due to mild to moderate visual impairment and $9.4 billion from severe visual impairment to blindness. The economic burden was estimated at $26.3 billion. The study authors concluded that myopia prevention and management strategies should aim to reduce the prevalence of myopia, prevent uncorrected refractive errors, and address the irreversible visual impairment caused by high myopia to alleviate these significant economic costs [31].
These findings emphasize that myopia is not just a refractive error; it is a serious ophthalmological condition that can lead to blindness and increased socioeconomic costs.

Epidemiology

Table 2 summarizes epidemiological studies of myopia published over the last 10 years. Collectively, they indicate that the incidence of myopia is increasing globally, with exceptionally high incidence rates in East Asia, including South Korea.

1. Global perspective

Vitale et al. reported a substantial increase in the prevalence of myopia in the United States from 25.0% in 1971−1972 to 41.6% in 1999−2004 [32]. Williams et al. [33] reported an overall prevalence of myopia in Europe of 30.6%, with a particularly high prevalence of 47.2% among adults aged 25−29 years. These studies analyzed differences based on ethnicity and educational levels. Holden et al. [1] predicted that the global prevalence of myopia would increase from approximately 23% (1.4 billion people) in 2000 to approximately 49.8% (5 billion people) by 2050.
The prevalence of myopia among young adults in East Asia is higher than that in Western countries and other regions [11]. In China, Li et al. [34] investigated the annual incidence of myopia progression and high myopia in schoolchildren from grades 1 to 6. They reported a substantial increase in the prevalence of myopia: the annual incidence increased from 7.8% in grades 1 and 2 to 25.3% in grades 5 and 6, while the incidence of high myopia increased from 0.1% to 1.0%. In Taiwan, a nationwide population- based study examined the prospective association between near-visual activity and incident myopia in children aged 7–12 over a 4-year follow-up period. The study showed that 26.8% of the children had myopia at baseline in 2010, while 27.7% of those without myopia at baseline developed incident myopia in 2010–2013. Consequently, more than 50% of children developed myopia during adolescence [35].

2. Korean data

The Korean National Health and Nutrition Examination Survey (KNHANES) conducted in a nationally representative cross-sectional cohort of 3,862 children showed that 2,495 of them (64.6%) had myopia, among whom 5.4% high myopia. The prevalence rate ratios (PRRs) for pediatric myopia and high myopia among children with myopic parents were 1.34 (95% confidence interval [CI], 1.24–1.45) and 3.11 (95% CI, 1.93–5.01), respectively. The PRRs of myopia and high myopia significantly increased to 1.37 (95% CI, 1.04–1.81) and 11.41 (95% CI, 6.24–20.88), respectively with higher degrees of parental myopia [36].

Possible mechanism of myopia progression

The peripheral hyperopic defocus theory, currently the most widely accepted explanation for the mechanism of myopia progression, describes a refractive anomaly in which light focuses behind the retina in the peripheral retinal area [37] (Fig. 1). This phenomenon is considered one of the primary mechanisms underlying myopia progression; the position of the light focus serves as a signal that regulates axial length growth [38]. Specifically, the eye detects peripheral hyperopic defocus and activates a growth mechanism that elongates the axial length compensatorily. During this process, optical defects in the peripheral retina determine eye growth direction and rate.

1. Myopia pathophysiology

The pathophysiological evidence of myopia can be broadly categorized into anatomical and biological changes. Researches demonstrated that myopia arises primarily from excessive axial elongation, which is closely associated with scleral remodeling [3,39]. The molecular mechanisms underlying this increase in axial length have been studied extensively. Ku et al. [40] identified a role for transforming growth factor-β in the signaling pathways of myopia and axial elongation of enhancing intraocular inflammation. Liu and Sun reported that insulin-like growth factor-1/signal transducer and activator of the transcription 3 pathway in the sclera may modulate metalloproteinase-2 expression, thus playing an essential role in scleral remodeling during myopia development [41,42].
Changes in choroidal thickness are a characteristic structural feature of myopia. Experimental studies revealed that the choroid actively and rapidly regulates eye growth [43,44]. Rapid variations in choroidal thickness under defocused or deprived conditions suggest its important role in this mechanism. Based on clinical observations, Flores-Moreno et al. [45] reported that axial length was significantly associated with choroidal thickness in patients with high myopia. In fact, the choroidal thickness profile differed between individuals with high myopia and those with emmetropia.
A choroidal blood flow reduction is also closely associated with myopia, particularly high myopia [46,47]. The observed changes included reduced vessel diameter and increased vessel wall rigidity. A notable finding was the impact of hypoxia resulting from reduced choroidal blood flow on myopia progression as demonstrated in animal myopia models [48] and human scleral fibroblasts [49]. The above research suggests that oxygen deficiency can induce structural scleral changes, ultimately accelerating axial length elongation and myopia progression.
Dopamine receptors play a critical role in myopia development [50]. In several animal studies, activated D1 receptors demonstrated the potential to inhibit myopia development. D2 receptors exhibited a biphasic effect in which low doses suppressed and high doses promoted myopia progression. D4 receptors are associated with an increased susceptibility to form-deprived myopia.

2. Myopia genetics

A meta-analysis of European populations that combined data from 9 different cohort studies involving 16,830 participants in a myopia analysis and 14,981 in a hyperopia analysis identified significant genetic variants in 2 key regions, 8q12 and 15q14, associated with myopia and hyperopia [51]. Notably, this study successfully replicated 11 previously reported genetic loci associated with myopia [52]. This research demonstrated that certain genetic factors could influence the myopic and hyperopic pathways, although in opposing directions.
A genome-wide association study conducted of a Han Chinese population of 3,222 patients and 6311 controls investigated the genetic factors associated with high myopia [53]. Significant genetic variants were identified in the 13q12.12 region, which contains the MIPEP, C1QTNF9B-AS1, and C1QTNF9B genes. Of them, MIPEP and C1QTNF9B are expressed in the retina and retinal pigment epithelium, suggesting their roles in myopia development.
Parental genetic factors play a crucial role in myopia development and progression. Research indicates that children with 2 myopic parents have a greater than 3 to 6 times the risk of developing juvenile-onset myopia than those whose parents are not myopic [54,55]. Additionally, a prospective study of primary school children in Beijing, China, confirmed that parental myopia is a key factor that increases the risk of myopia among children [56]. Despite the consideration of variables such as parental myopia status, a child's near-work time, and academic achievement, parental myopia remained an independent risk factor [57]. More importantly, parental myopia affects age at myopia onset as well as progression in children. A study of Singaporean children revealed that earlier-onset myopia and parental high myopia significantly increased a child's risk of developing high myopia in later childhood [58]. The Correction of Myopia Evaluation Trial further confirmed this genetic influence, showing that children with 2 myopic parents experienced a significantly greater progression of myopia than those with one or no myopic parents. Notably, this parental effect was less pronounced in children wearing progressive addition versus single-vision lenses, suggesting potential interactions between genetic predisposition and treatment approach [59].

Relationship between nonophthalmological conditions and myopia in children and adolescents

1. Body stature

Li et al. identified a positive correlation between height and axial length, both of which are important factors in the development and progression of myopia [60]. Their study of preschool children aged 3–6 years from 10 randomly selected kindergartens revealed that taller children had longer axial lengths. Machluf et al. [61] reported an elevated risk of bilateral myopia associated with body mass index alone or with both height and weight in boys.
Obesity is associated with high myopia in children and adolescents. The National Health and Nutrition Examination Survey, which included 9008 adolescents in the USA, reported associations between weight, body mass index, and the occurrence of myopia [62]. The survey indicated that height and ethnicity correlated with degree of myopia.
The KNHANES showed that obese children and adolescents were 3.77-fold more likely to develop high myopia than normal-weight individuals. Significant sex-related differences were observed; obese girls had a 5.04-fold higher risk, whereas obese boys had a 2.84-fold higher risk. Researchers identified insulin resistance, which is present in 15%–20% of children with obesity, as a significant contributing factor [63].

2. Sleep patterns

A study in South Korea demonstrated that the odds of developing myopia were 41% lower among individuals sleeping more than 9 hours per night than among those sleeping less than 5 hours per night [64]. Additionally, Australian university students with myopia averaged 7.18 hours of sleep versus 8.46 hours in those without myopia [65]. In addition to sleep duration, bedtime was a significant factor, with several studies finding that later bedtimes are associated with myopia [66,67]. In contrast, a study in Singapore showed no independent association between sleep quality, duration, timing, or consistency of specific sleep factors and myopia in elementary school–aged children [68]. Another study showed that sleep duration and quality at 12 months of age were not associated with refractive error at 3 years of age [69]. Thus, further research is required to clarify the relationship between sleep patterns and myopia.

3. Nutritional status

Yin et al. [70] reported that a balanced diet including meat, seafood, dairy products, eggs, legumes, vegetables, fruits, grains, and potatoes may protect against myopia. Kim and Choi [71] examined the role of diet and lifestyle choices in the development of myopia in children using data from 24,345 children aged 5–12 years from the KNHANES. They reported that children with myopia had significantly lower intakes of fat, omega-3 fatty acids, and retinol but higher intake of other nutrients relative to their emmetropic and hyperopic counterparts. High dietary levels of carbohydrates, proteins, phosphorus, iron, potassium, and sodium have been associated with an increased risk of myopia. Notably, a high sodium intake was associated with a 2.05-fold higher risk of myopia.
The consumption of foods with a high glycemic index has also been associated with the development of myopia. Cordain et al. [72] reported that the excessive intake of such foods promotes insulin resistance, while the resulting elevation in blood insulin levels stimulates insulin-like growth factor 1 secretion, which can increase axial length and contribute to myopia development. Conversely, fruit consumption may protect against myopia. Zhang et al. [73] reported that the phytochemicals in fruits, particularly carotenoids, may help prevent myopia.
A link between salt intake and myopia was recently established. Dietary sodium chloride increases the ionic permeability of the retinal membranes, leading to fluid accumulation in the vitreous. This process stretches the ocular tissue, ultimately resulting in axial myopia [74].

Treatment and prevention

Table 3 summarizes the most effective treatments for myopia progression.

1. Optical devices

Spectacles are conventional optical devices that are used to correct refractive errors. In animal experiments using chicks, monocular deprivation of form vision caused myopia and increased axial length [75], suggesting that spectacles that appropriately correct refractive errors can primarily help inhibit the progression of myopia. Human clinical studies demonstrated that the accurate prescription of spectacles and regular follow-up of refractive error monitoring are important for myopia management, including cases of myopia-induced amblyopia [76]. Spectacles are not associated with vision-threatening complications or systemic side effects, making them a safe primary approach. However, spectacles alone cannot effectively prevent the progression of myopia. Several recent studies demonstrated that defocus-incorporated multisegment spectacle (DIMS) lenses can effectively control myopia [77-81]. DIMS lenses consist of a central distance optical zone (diameter, 9 mm) surrounded by an annular midperipheral zone containing 396 small round segments (diameter, approximately 1.03 mm), each with a +3.50 D add power. These lenses allow clear central vision while introducing myopic defocus into the peripheral retina [77,82]. As described above in the Possible Mechanism of Myopia Progression section, myopic and hyperopic defocus are complementary theories that explain how the position of the focal point of the retina regulates eye growth (Fig. 2). Hyperopic defocus (focusing in front of the retina) promotes eye growth and exacerbates myopia, whereas myopic defocus (focusing behind the retina) inhibits eye growth and slows the progression of myopia, demonstrating the bidirectional actions of the same visual feedback system.
Orthokeratology is a nonsurgical procedure that uses specially designed contact lenses to temporarily reshape the cornea during sleep and improve an individual's vision. The design of the orthokeratology lens creates controls pressure on the central cornea, thereby flattening this area. This geometric modification produces the refractive power change required for myopia correction. The pressure exerted by the lens causes the corneal epithelial cells to migrate from the central to peripheral cornea, leading to thinning of the central corneal region while simultaneously thickening the peripheral areas and effectively reshaping the corneal surface. During this process, the tear layer between the lens and the cornea generates hydrodynamic forces that facilitate corneal molding [83-85]. The correction of myopia up to -6.0 D is achieved through central corneal epithelial thinning and midperipheral epithelial and stromal thickening. Recent studies reported that orthokeratology effectively slows the progression of myopia by preventing axial length elongation [14,86-89].
However, orthokeratology can occasionally cause acanthamoeba keratitis [90,91] or bacterial keratitis [92,93] when lens management is inadequate; these conditions are more common in children and adolescents [94]. Despite early intervention and treatment, most infections result in the formation of corneal scars; almost 10% of affected eyes require surgical treatment [94]. Therefore, daily lens cleaning and disinfection protocols, including rubbing and rinsing lenses with prescribed solutions prior to storage, are strictly recommended [95].
Rebounding, which presents another challenge in orthokeratology, is defined as the accelerated progression of myopia that occurs after the discontinuation of any myopia control treatment [96-100]. Cho and Cheung [96] found that stopping orthokeratology at or before 14 years of age led to a more rapid increase in axial length compared to those wearing spectacles and those in continuous orthokeratology groups. However, axial elongation slowed again with the resumption of orthokeratology after 6 months. Therefore, if orthokeratology treatment begins before 14 years of age, it is crucial to select children who can maintain treatment consistency [100]. However, the optimal treatment duration and progressive reduction strategies to prevent the progression of myopia require further investigation.
Conversely, myopia undercorrection, blue light–blocking glass use, and rigid gas-permeable contact lens wear have no or minimal effects on myopia progression [101-105].

2. Pharmacological treatments

Atropine nonselectively blocks muscarinic receptors located in the human ciliary muscle, retina, and sclera [106]. Although the precise mechanism of atropine in myopia control remains unknown, it is thought to act directly or indirectly on the retina or sclera, inhibiting scleral thinning or stretching and thereby preventing eye growth [107-113].
Research on diluted atropine eye drops in Taiwan led to significantly improved myopia control. The Atropine for the Treatment of Myopia clinical trials in particular influenced this field. Chia et al. [114] demonstrated that different concentrations of atropine exhibited varying degrees of efficacy at controlling myopia progression.
The Low-Concentration Atropine for Myopia Progression study provided critical evidence of the efficacy of low-concentration atropine. The 0.05%, 0.025%, and 0.01% atropine eye drops effectively controlled myopia progression in a concentration-dependent manner [115]. Additionally, 0.05% atropine offers an optimal balance between efficacy and side effects, with minimal rebound effects after its discontinuation [116,117].
Through large-scale studies demonstrating effective results, low-concentration atropine eye drops have become the preferred treatment for controlling myopia progression.
However, atropine eye drops exhibit several adverse effects. Pupil dilation can cause photophobia, leading to discomfort upon exposure to bright light [115] and near-vision reduction, although these effects are often minimal at low doses [118,119]. If atropine passes through the puncta into the nasolacrimal duct and is subsequently absorbed through the nasal mucosa, it can carry systemic side effects such as dry mouth, flushing, drowsiness, and tachycardia [107,120,121]. Therefore, even at low concentrations, it is necessary to take precautions to prevent systemic side effects by compressing the puncta with the fingers for some time after eyedrop instillation.
Atropine eye drops can also lead to rebound [97]. When high-concentration atropine eye drops (0.5% and 0.1%) were used, a rapid progression of myopia was observed after discontinuation [98]. However, no significant rebound was observed when low-concentration atropine eye drops (0.025% and 0.01%) were used for 2 years and then discontinued. With 0.05% atropine eye drops, faster axial growth (0.04 mm) was observed during the first year postdiscontinuation, which was considered clinically insignificant. Moreover, children aged 6–8 years showed similar rates of eye growth postdiscontinuation all concentrations (0.05%, 0.025%, 0.01%) [99]. Based on the research conducted to date, the recommendation involves using either use low-concentration atropine eye drops (0.025%, 0.01%) from the beginning, or for those using higher concentrations, gradually tapering down to low-concentration atropine eye drops and maintaining this regimen for at least 2 years to help prevent rebound.

3. Behavioral treatments

Numerous studies have established an association between near work and myopia progression. Recent systematic reviews and meta-analyses have suggested that the increased use of digital devices such as smartphones and tablets is linked to a higher risk of myopia. Specifically, increased digital device use was associated with a 1.26-fold (95% CI, 1.00–1.60) higher risk of myopia; total digital screen time, including computer use, was associated with a 1.77-fold (95% CI, 1.28–2.45) higher risk [122]. Near-work activities performed at distances shorter than 20 cm significantly increase the risk of myopia development [123,124]. These findings suggest that near-work activities, including digital device use, are significant environmental risk factors for the progression of myopia in children and adolescents.
Outdoor activities are an important strategy in the management of myopia progression. Rose et al. [125] reported that at least 2 hours of daylight exposure can help prevent the onset of myopia in children of myopic parents who do not yet have myopia. The Family Incentive Trial in Singapore confirmed that weekend outdoor intervention programs significantly increased children's outdoor time. These findings suggest that structured outdoor activities can prevent myopia prevention in children [126]. In addition, a Taiwanese study of 571 children aged 7–11 years showed that the Recess Outside the Classroom Program significantly reduced the incidence of myopia in the intervention versus control group. Among the nonmyopic participants, the progression of myopia was significantly lower in the intervention group [127].
Research regarding this relationship was conducted during the coronavirus disease 2019 pandemic, when outdoor activities were restricted. Two studies revealed a significant myopic shift and increased prevalence of myopia during this period, particularly among children [10,128]. Another study demonstrated that daily digital device use increased from 0.67 to 5.24 hours per day; faster progression was observed in children using phones and tablets versus those using televisions or projectors [129].
Additionally, regarding nonophthalmological conditions, as mentioned in the relationship between nonophthalmological conditions and myopia in children and adolescents section, adequate sleep duration and regular sleep patterns, along with a healthy body weight and an appropriate diet (including reduced sodium intake and increased fruit consumption), are thought to help prevent myopia.

Interventional attempts to prevent progression from premyopia to myopia

Studies have focused on preventing the progression from premyopia to myopia. As this stage precedes the need for myopic correction, the primary goal is to prevent myopia onset. The results of several studies have supported this approach. Mutti et al. [37] demonstrated that axial length changes occurred before the clinical onset of myopia. Two studies reported that cycloplegic refraction or ocular biometric measurements (e.g., axial length and corneal curvature) could predict myopia progression in premyopic children, emphasizing the importance of early intervention in preventing the transition from premyopia to myopia [130,131]. Fang et al. [132] reported that low-dose atropine (0.025%) effectively reduced the progression of premyopia to myopia. Furthermore, a large cohort study evaluating the effect of outdoor time per school day over 2 years indicated that increasing outdoor time reduced the risk of myopia onset and myopic shifts, particularly among nonmyopic children [133].

Regular retinal monitoring

Considering the ophthalmologic risks associated with myopia, as previously mentioned in the Importance of Myopia in Ophthalmology section, regular eye examinations, including fundus examinations and optical coherence tomography (OCT), are essential for myopic patients, especially those with high myopia. For children with high myopia or rapidly progressing myopia, regular dilated fundus examinations and OCT imaging (e.g., annually) are recommended to monitor early pathological changes [134]. A fundus examination through fundus photography can detect chorioretinal atrophy, lacquer cracks, and myopic choroidal neovascularization, all of which can contribute to visual deterioration and escalate the socioeconomic burden.
OCT is a noninvasive imaging technique that employs the principle of light interference to generate high-resolution cross-sectional images of biological tissues. In patients with high myopia, OCT plays a key role in identifying early structural changes in the retina and choroid, facilitating the early diagnosis and management of complications such as myopic maculopathy and choroidal neovascularization [135]. A study of pediatric myopia using OCT indicated that foveal thickness increased with age and myopia. Choroid volume, vessel volume, and temporal choroid thickness also increase with increasing myopia [136]. In another study, children and adolescents with high myopia exhibited thinner macula along with reduced vessel density in the superficial and deep capillary plexuses and a wider foveal avascular zone compared to their age-matched emmetropes [137]. These studies suggest that OCT can effectively screen for progression of pediatric myopia.
These regular retinal monitoring examinations can significantly influence treatment decisions, such as implementing more intensive axial length control strategies when early signs of maculopathy are detected or when choroidal neovascularization develops and antivascular endothelial growth factor therapy is initiated. Early intervention based on these results can help preserve vision and prevent irreversible structural damage to the retina [135].

Conclusion

The prevalence of myopia is increasing rapidly worldwide, particularly in East Asia. Thus, its early detection and appropriate management are required because of its association with serious ophthalmic complications. Myopia is closely linked to genetic and systemic factors including body stature, sleep patterns, and nutritional status. An integrated management approach that considers children’s systemic health may be necessary rather than relying solely on ophthalmological treatment. Future research should prioritize the development of effective prevention strategies to halt the progression from premyopia to myopia as well as the continuous development and validation of new management approaches tailored to modern society, which is increasingly reliant on digital devices.

Footnotes

Conflicts of interest

No potential conflict of interest relevant to this article was reported.

Funding

This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Fig. 1.
Schematic view of peripheral hyperopic defocus theory.
cep-2025-00115f1.jpg
Fig. 2.
Schematic view of peripheral myopic defocus theory.
cep-2025-00115f2.jpg
Table 1.
Quantitative definition of myopia
Myopia Definition
Spherical equivalent refractive error when ocular accommodation is relaxed.
Premyopia ≤+0.75 D and >-0.50 D
Low myopia ≤-0.50 and >-6.00 D
High myopia ≤-6.00 D

D, diopters.

Table 2.
Population-based epidemiological studies of myopia published in the last 10 years
Study Country Study period Database Population Incidence of myopia Trend during study period
Holden et al. [1] Global 1995–2015 145 Studies covering 2.1 million participants All ages 22.9% (in 2000) Increase (to 49.8% by 2050)
Vitale et al. [32] USA 1971–1972 vs. 1999–2004 National Health and Nutrition Examination Surveys Age 12–54 years 25.0% (1971–1972) to 41.6% (1999–2004) Increase by 66.4% over 30 years
Williams et al. [33] Europe 1990–2013 15 Population-based cohort and cross-sectional studies ≥25 to <90 years 24.2% (in 2010) Increase (to 30.6% by 2050)
Li et al. [34] China 2012–2017 Cohort study from 11 elementary schools in Anyang City Students grade 1 (5-year follow-up) 7.8% in grade 1–2 to 25.3% in grade 5–6 Substantial progression from +0.94 D to -1.37 D
Ku et al. [35] Taiwan 2009–2013 National Health Interview Survey and National Health Insurance claims data 7–12 Years 26.8% at baseline 27.7% increase in those without myopia at baseline
Lim et al. [36] South Korea 2008–2012 Korean National Health and Nutrition Examination Surveys 5–18 Years 64.6% overall, 5.4% high myopia High prevalence and strong association with parental myopia (PRR, 1.34; 95% CI, 1.24–1.45)

CI, confidence interval; D, diopter; PRR, prevalence rate ratio.

Table 3.
Effective treatment options for preventing myopia progression
Category Details
Optical Defocus-incorporated multisegment spectacle lens
Orthokeratology
Pharmacological Diluted atropine eyedrop (0.05%)
Behavioral Ophthalmological
 Near work or digital device use at distances of at least 20 cm
 Outdoor activities for a minimum of 1–2 hours daily
Nonophthalmological
 Adequate sleep duration and regular sleep patterns
 Body weight control
 Appropriate diet (e.g., reduced sodium intake and fruit consumption)

References

1. Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology 2016;123:1036–42.
crossref pmid
2. Flitcroft DI, He M, Jonas JB, Jong M, Naidoo K, Ohno-Matsui K, et al. IMI - defining and classifying myopia: a proposed set of standards for clinical and epidemiologic studies. Invest Ophthalmol Vis Sci 2019;60:M20–30.
crossref pmid pmc
3. Ohno-Matsui K, Wu PC, Yamashiro K, Vutipongsatorn K, Fang Y, Cheung CMG, et al. IMI pathologic myopia. Invest Ophthalmol Vis Sci 2021;62:5.
crossref pmid pmc
4. Meng W, Butterworth J, Malecaze F, Calvas P. Axial length of myopia: a review of current research. Ophthalmologica 2011;225:127–34.
crossref pmid pdf
5. Tedja MS, Haarman AEG, Meester-Smoor MA, Kaprio J, Mackey DA, Guggenheim JA, et al. IMI - myopia genetics report. Invest Ophthalmol Vis Sci 2019;60:M89–105.
crossref pmid pmc
6. Wojciechowski R. Nature and nurture: the complex genetics of myopia and refractive error. Clin Genet 2011;79:301–20.
crossref pmid pmc
7. Wu PC, Huang HM, Yu HJ, Fang PC, Chen CT. Epidemiology of myopia. Asia Pac J Ophthalmol (Phila) 2016;5:386–93.
pmid
8. Fan Q, Wojciechowski R, Kamran Ikram M, Cheng CY, Chen P, Zhou X, et al. Education influences the association between genetic variants and refractive error: a meta-analysis of five Singapore studies. Hum Mol Genet 2014;23:546–54.
crossref pmid pmc
9. Rose K, Harper R, Tromans C, Waterman C, Goldberg D, Haggerty C, et al. Quality of life in myopia. Br J Ophthalmol 2000;84:1031–4.
crossref pmid pmc
10. Wang J, Li Y, Musch DC, Wei N, Qi X, Ding G, et al. Progression of myopia in school-aged children after COVID-19 home confinement. JAMA Ophthalmol 2021;139:293–300.
crossref pmid pmc
11. Morgan IG, French AN, Ashby RS, Guo X, Ding X, He M, et al. The epidemics of myopia: aetiology and prevention. Prog Retin Eye Res 2018;62:134–49.
crossref pmid
12. Xiong S, Sankaridurg P, Naduvilath T, Zang J, Zou H, Zhu J, et al. Time spent in outdoor activities in relation to myopia prevention and control: a meta-analysis and systematic review. Acta Ophthalmol 2017;95:551–66.
crossref pmid pmc pdf
13. Saw SM, Gazzard G, Shih-Yen EC, Chua WH. Myopia and associated pathological complications. Ophthalmic Physiol Opt 2005;25:381–91.
crossref pmid
14. Kim J, Lim DH, Han SH, Chung TY. Predictive factors associated with axial length growth and myopia progression in orthokeratology. PLoS One 2019;14:e0218140.
crossref pmid pmc
15. Wong TY, Ferreira A, Hughes R, Carter G, Mitchell P. Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review. Am J Ophthalmol 2014;157:9–25.e12.
crossref pmid
16. Pan CW, Cheng CY, Saw SM, Wang JJ, Wong TY. Myopia and age-related cataract: a systematic review and meta-analysis. Am J Ophthalmol 2013;156:1021–33.e1.
crossref pmid
17. Yap A, Meyer JJ. Degenerative myopia. 2022 Sep 19. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–.

18. Risk factors for idiopathic rhegmatogenous retinal detachment. The eye disease case-control study group. Am J Epidemiol 1993;137:749–57.
crossref pmid
19. Schepens CL, Marden D. Data on the natural history of retinal detachment. I. Age and sex relationships. Arch Ophthalmol 1961;66:631–42.
crossref pmid
20. Polkinghorne PJ, Craig JP. Northern New Zealand Rhegmatogenous Retinal Detachment Study: epidemiology and risk factors. Clin Exp Ophthalmol 2004;32:159–63.
crossref pmid
21. Parolini B, Palmieri M, Finzi A, Besozzi G, Frisina R. Myopic traction maculopathy: a new perspective on classification and management. Asia Pac J Ophthalmol (Phila) 2021;10:49–59.
crossref pmid
22. Parolini B, Palmieri M, Finzi A, Besozzi G, Lucente A, Nava U, et al. The new myopic traction maculopathy staging system. Eur J Ophthalmol 2021;31:1299–312.
crossref pmid pdf
23. Pierro L, Camesasca FI, Mischi M, Brancato R. Peripheral retinal changes and axial myopia. Retina 1992;12:12–7.
crossref pmid
24. Karlin DB, Curtin BJ. Peripheral chorioretinal lesions and axial length of the myopic eye. Am J Ophthalmol 1976;81:625–35.
crossref pmid
25. Nakao Y, Kimura T. Prevalence and anatomic mechanism of highly myopic strabismus among Japanese with severe myopia. Jpn J Ophthalmol 2014;58:218–24.
crossref pmid pdf
26. Yamaguchi M, Yokoyama T, Shiraki K. Surgical procedure for correcting globe dislocation in highly myopic strabismus. Am J Ophthalmol 2010;149:341–6.e2.
crossref pmid
27. Krzizok TH, Schroeder BU. Measurement of recti eye muscle paths by magnetic resonance imaging in highly myopic and normal subjects. Invest Ophthalmol Vis Sci 1999;40:2554–60.
pmid
28. Ramakrishnan MS, Patel AP, Melles R, Vora RA. Multiple evanescent white dot syndrome: findings from a large Northern California cohort. Ophthalmol Retina 2021;5:850–4.
crossref pmid
29. Jonas JB, Panda-Jonas S, Wei WB, Xu J, Wang YX. Prevalence and associations of dome-shaped maculas. The Beijing Eye Study. Acta Ophthalmol 2025;103:177–85.
crossref pmid
30. Chang RT, Singh K. Myopia and glaucoma: diagnostic and therapeutic challenges. Curr Opin Ophthalmol 2013;24:96–101.
pmid
31. Ma Y, Wen Y, Zhong H, Lin S, Liang L, Yang Y, et al. Healthcare utilization and economic burden of myopia in urban China: a nationwide cost-of-illness study. J Glob Health 2022;12:11003.
crossref pmid pmc
32. Vitale S, Sperduto RD, Ferris FL 3rd. Increased prevalence of myopia in the United States between 1971-1972 and 1999-2004. Arch Ophthalmol 2009;127:1632–9.
crossref pmid
33. Williams KM, Verhoeven VJ, Cumberland P, Bertelsen G, Wolfram C, Buitendijk GH, et al. Prevalence of refractive error in Europe: the European Eye Epidemiology (E(3)) Consortium. Eur J Epidemiol 2015;30:305–15.
crossref pmid pmc pdf
34. Li SM, Wei S, Atchison DA, Kang MT, Liu L, Li H, et al. Annual incidences and progressions of myopia and high myopia in Chinese schoolchildren based on a 5-year cohort study. Invest Ophthalmol Vis Sci 2022;63:8.
crossref pmid pmc
35. Ku PW, Steptoe A, Lai YJ, Hu HY, Chu D, Yen YF, et al. The associations between near visual activity and incident myopia in children: a nationwide 4-year follow-up study. Ophthalmology 2019;126:214–20.
crossref pmid
36. Lim DH, Han J, Chung TY, Kang S, Yim HW, Epidemiologic Survey Committee of the Korean Ophthalmologic Society. The high prevalence of myopia in Korean children with influence of parental refractive errors: the 2008-2012 Korean National Health and Nutrition Examination Survey. PLoS One 2018;13:e0207690.
crossref pmid pmc
37. Mutti DO, Hayes JR, Mitchell GL, Jones LA, Moeschberger ML, Cotter SA, et al. Refractive error, axial length, and relative peripheral refractive error before and after the onset of myopia. Invest Ophthalmol Vis Sci 2007;48:2510–9.
crossref pmid pmc
38. Smith EL 3rd. Optical treatment strategies to slow myopia progression: effects of the visual extent of the optical treatment zone. Exp Eye Res 2013;114:77–88.
crossref pmid pmc
39. Cassagne M, Malecaze F, Soler V. Physiopathologie de la myopie, entre hérédité et environnement [Pathophysiology of myopia: nature versus nurture]. J Fr Ophtalmol 2014;37:407–14.
pmid
40. Ku H, Chen JJ, Chen W, Tien PT, Lin HJ, Wan L, et al. The role of transforming growth factor beta in myopia development. Mol Immunol 2024;167:34–42.
crossref pmid
41. Yu Q, Zhou JB. Scleral remodeling in myopia development. Int J Ophthalmol 2022;15:510–4.
crossref pmid pmc
42. Liu YX, Sun Y. MMP-2 participates in the sclera of guinea pig with form-deprivation myopia via IGF-1/STAT3 pathway. Eur Rev Med Pharmacol Sci 2018;22:2541–8.
pmid
43. Wallman J, Winawer J. Homeostasis of eye growth and the question of myopia. Neuron 2004;43:447–68.
crossref pmid
44. Nickla DL, Wallman J. The multifunctional choroid. Prog Retin Eye Res 2010;29:144–68.
crossref pmid
45. Flores-Moreno I, Lugo F, Duker JS, Ruiz-Moreno JM. The relationship between axial length and choroidal thickness in eyes with high myopia. Am J Ophthalmol 2013;155:314–9.e1.
crossref pmid
46. Yang YS, Koh JW. Choroidal blood flow change in eyes with high myopia. Korean J Ophthalmol 2015;29:309–14.
crossref pmid pmc
47. Wakabayashi T, Ikuno Y. Choroidal filling delay in choroidal neovascularisation due to pathological myopia. Br J Ophthalmol 2010;94:611–5.
crossref pmid
48. Zhang S, Zhang G, Zhou X, Xu R, Wang S, Guan Z, et al. Changes in choroidal thickness and choroidal blood perfusion in guinea pig myopia. Invest Ophthalmol Vis Sci 2019l;60:3074–83.
crossref
49. Wu H, Chen W, Zhao F, Zhou Q, Reinach PS, Deng L, et al. Scleral hypoxia is a target for myopia control. Proc Natl Acad Sci U S A 2018;115:E7091–100.
crossref pmid pmc
50. Zhou X, Pardue MT, Iuvone PM, Qu J. Dopamine signaling and myopia development: what are the key challenges. Prog Retin Eye Res 2017;61:60–71.
crossref pmid pmc
51. Simpson CL, Wojciechowski R, Oexle K, Murgia F, Portas L, Li X, et al. Genome-wide meta-analysis of myopia and hyperopia provides evidence for replication of 11 loci. PLoS One 2014;9:e107110.
crossref pmid pmc
52. Kiefer AK, Tung JY, Do CB, Hinds DA, Mountain JL, Francke U, et al. Genome-wide analysis points to roles for extracellular matrix remodeling, the visual cycle, and neuronal development in myopia. PLoS Genet 2013;9:e1003299.
crossref pmid pmc
53. Shi Y, Qu J, Zhang D, Zhao P, Zhang Q, Tam POS, et al. Genetic variants at 13q12.12 are associated with high myopia in the Han Chinese population. Am J Hum Genet 2011;88:805–13.
pmid pmc
54. Farbrother JE, Kirov G, Owen MJ, Guggenheim JA. Family aggregation of high myopia: estimation of the sibling recurrence risk ratio. Invest Ophthalmol Vis Sci 2004;45:2873–8.
crossref pmid
55. Pacella R, McLellan J, Grice K, Del Bono EA, Wiggs JL, Gwiazda JE. Role of genetic factors in the etiology of juvenile- onset myopia based on a longitudinal study of refractive error. Optom Vis Sci 1999;76:381–6.
crossref pmid
56. Wu LJ, Wang YX, You QS, Duan JL, Luo YX, Liu LJ, et al. Risk factors of myopic shift among primary school children in Beijing, China: a prospective study. Int J Med Sci 2015;12:633–8.
crossref pmid pmc
57. Mutti DO, Mitchell GL, Moeschberger ML, Jones LA, Zadnik K. Parental myopia, near work, school achievement, and children's refractive error. Invest Ophthalmol Vis Sci 2002;43:3633–40.
pmid
58. Chua SY, Sabanayagam C, Cheung YB, Chia A, Valenzuela RK, Tan D, et al. Age of onset of myopia predicts risk of high myopia in later childhood in myopic Singapore children. Ophthalmic Physiol Opt 2016;36:388–94.
crossref pmid
59. Kurtz D, Hyman L, Gwiazda JE, Manny R, Dong LM, Wang Y, et al. Role of parental myopia in the progression of myopia and its interaction with treatment in COMET children. Invest Ophthalmol Vis Sci 2007;48:562–70.
crossref pmid
60. Li L, Liao C, Zhang X, Lu J, Zeng Y, Fu M, et al. Association between body stature with ocular biometrics and refraction among Chinese preschoolers. BMC Ophthalmol 2024;24:107.
crossref pmid pmc pdf
61. Machluf Y, Israeli A, Cohen E, Chaiter Y, Mezer E. Dissecting the complex sex-based associations of myopia with height and weight. Eye (Lond) 2024;38:1485–95.
crossref pmid pmc pdf
62. Chen N, Sheng Y, Wang G, Liu J. Association between physical indicators and myopia in American Adolescents: National Health and Nutrition Examination Survey 1999-2008. Am J Ophthalmol 2024;260:132–9.
crossref pmid
63. Lee S, Lee HJ, Lee KG, Kim J. Obesity and high myopia in children and adolescents: Korea National Health and Nutrition Examination Survey. PLoS One 2022;17:e0265317.
crossref pmid pmc
64. Jee D, Morgan IG, Kim EC. Inverse relationship between sleep duration and myopia. Acta Ophthalmol 2016;94:e204. –10.
crossref pmid
65. Chakraborty R, Micic G, Thorley L, Nissen TR, Lovato N, Collins MJ, et al. Myopia, or near-sightedness, is associated with delayed melatonin circadian timing and lower melatonin output in young adult humans. Sleep 2021;44:zsaa208.
crossref pmid pdf
66. Liu XN, Naduvilath TJ, Wang J, Xiong S, He X, Xu X, et al. Sleeping late is a risk factor for myopia development amongst school-aged children in China. Sci Rep 2020;10:17194.
crossref pmid pmc pdf
67. Qu Y, Yu J, Xia W, Cai H. Correlation of myopia with physical exercise and sleep habits among suburban adolescents. J Ophthalmol 2020;2020:2670153.
crossref pmid pmc pdf
68. Li M, Tan CS, Xu L, Foo LL, Yap F, Sun CH, et al. Sleep Patterns and myopia among school-aged children in Singapore. Front Public Health 2022;10:828298.
crossref pmid pmc
69. Sensaki S, Sabanayagam C, Chua S, Htoon HM, Broekman BFP, Thiam DGY, et al. Sleep duration in infants was not associated with myopia at 3 years. Asia Pac J Ophthalmol (Phila) 2018;7:102–8.
pmid
70. Yin C, Gan Q, Xu P, Yang T, Xu J, Cao W, et al. Dietary patterns and associations with myopia in Chinese children. Nutrients 2023;15:1946.
crossref pmid pmc
71. Kim JM, Choi YJ. Nutritional intake, environmental factors, and their impact on myopia prevalence in Korean children aged 5-12 years. J Health Popul Nutr 2024;43:14.
crossref pmid pmc pdf
72. Cordain L, Eaton SB, Brand Miller J, Lindeberg S, Jensen C. An evolutionary analysis of the aetiology and pathogenesis of juvenile-onset myopia. Acta Ophthalmol Scand 2002;80:125–35.
crossref pmid pdf
73. Zhang D, Wu M, Yi X, Shi J, Ouyang Y, Dong N, et al. Correlation analysis of myopia and dietary factors among primary and secondary school students in Shenyang, China. Sci Rep 2024;14:20619.
crossref pmid pmc pdf
74. Brown RB. Myopia, sodium chloride, and vitreous fluid imbalance: a nutritional epidemiology perspective. Epidemiologia (Basel) 2024;5:29–40.
crossref pmid pmc
75. Wallman J, Turkel J, Trachtman J. Extreme myopia produced by modest change in early visual experience. Science 1978;201:1249–51.
crossref pmid
76. Gifford KL, Richdale K, Kang P, Aller TA, Lam CS, Liu YM, et al. IMI - clinical management guidelines report. Invest Ophthalmol Vis Sci 2019;60:M184–203.
crossref pmid
77. Lam CSY, Tang WC, Tse DY, Lee RPK, Chun RKM, Hasegawa K, et al. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. Br J Ophthalmol 2020;104:363–8.
crossref pmid pmc
78. Zhang H, Lam CSY, Tang WC, Leung M, Qi H, Lee PH, et al. Myopia control effect is influenced by baseline relative peripheral refraction in children wearing defocus incorporated multiple segments (DIMS) spectacle lenses. J Clin Med 2022;11:2294.
crossref pmid pmc
79. Kaymak H, Neller K, Schütz S, Graff B, Sickenberger W, Langenbucher A, et al. Vision tests on spectacle lenses and contact lenses for optical myopia correction: a pilot study. BMJ Open Ophthalmol 2022;7:e000971.
crossref pmid pmc
80. Carlà MM, Boselli F, Giannuzzi F, Gambini G, Caporossi T, De Vico U, et al. Overview on defocus incorporated multiple segments lenses: a novel perspective in myopia progression management. Vision (Basel) 2022;6:20.
crossref pmid pmc
81. Lu Y, Lin Z, Wen L, Gao W, Pan L, Li X, et al. The adaptation and acceptance of defocus incorporated multiple segment lens for Chinese children. Am J Ophthalmol 2020;211:207–16.
crossref pmid
82. Nickla DL, Thai P, Zanzerkia Trahan R, Totonelly K. Myopic defocus in the evening is more effective at inhibiting eye growth than defocus in the morning: Effects on rhythms in axial length and choroid thickness in chicks. Exp Eye Res 2017;154:104–15.
crossref pmid pmc
83. Soni PS, Nguyen TT, Bonanno JA. Overnight orthokeratology: visual and corneal changes. Eye Contact Lens 2003;29:137–45.
pmid
84. Weiss JL. Circumferential anterior- and posterior-based wedge keratectomies: novel refractive procedures. Cornea 1991;10:127–30.
crossref pmid
85. Joe JJ, Marsden HJ, Edrington TB. The relationship between corneal eccentricity and improvement in visual acuity with orthokeratology. J Am Optom Assoc 1996;67:87–97.
pmid
86. Cho P, Cheung SW, Edwards M. The longitudinal orthokeratology research in children (LORIC) in Hong Kong: a pilot study on refractive changes and myopic control. Curr Eye Res 2005;30:71–80.
crossref pmid
87. Cho P, Cheung SW. Retardation of myopia in Orthokeratology (ROMIO) study: a 2-year randomized clinical trial. Invest Ophthalmol Vis Sci 2012;53:7077–85.
crossref pmid
88. Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Gutiérrez-Ortega R. Myopia control with orthokeratology contact lenses in Spain: refractive and biometric changes. Invest Ophthalmol Vis Sci 2012;53:5060–5.
crossref pmid
89. Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Gutiérrez-Ortega R. Factors preventing myopia progression with orthokeratology correction. Optom Vis Sci 2013;90:1225–36.
crossref pmid
90. Kaufman AR, Tu EY. Advances in the management of Acanthamoeba keratitis: A review of the literature and synthesized algorithmic approach. Ocul Surf 2022;25:26–36.
crossref pmid
91. Wu J, Xie H. Orthokeratology lens-related Acanthamoeba keratitis: case report and analytical review. J Int Med Res 2021;49:3000605211000985.
crossref pmid pmc pdf
92. Jung S, Eom Y, Song JS, Hyon JY, Jeon HS. Clinical features and visual outcome of infectious keratitis associated with orthokeratology lens in Korean Pediatric Patients. Korean J Ophthalmol 2024;38:399–412.
crossref pmid pmc pdf
93. Bullimore MA, Mirsayafov DS, Khurai AR, Kononov LB, Asatrian SP, Shmakov AN, et al. Pediatric microbial keratitis with overnight orthokeratology in Russia. Eye Contact Lens 2021;47:420–5.
crossref pmid
94. Kam KW, Yung W, Li GKH, Chen LJ, Young AL. Infectious keratitis and orthokeratology lens use: a systematic review. Infection 2017;45:727–35.
crossref pmid pdf
95. Stapleton F, Carnt N. Contact lens-related microbial keratitis: how have epidemiology and genetics helped us with pathogenesis and prophylaxis. Eye (Lond) 2012;26:185–93.
crossref pmid pmc pdf
96. Cho P, Cheung SW. Discontinuation of orthokeratology on eyeball elongation (DOEE). Cont Lens Anterior Eye 2017;40:82–7.
crossref pmid
97. Tong L, Huang XL, Koh AL, Zhang X, Tan DT, Chua WH. Atropine for the treatment of childhood myopia: effect on myopia progression after cessation of atropine. Ophthalmology 2009;116:572–9.
crossref pmid
98. Chia A, Chua WH, Wen L, Fong A, Goon YY, Tan D. Atropine for the treatment of childhood myopia: changes after stopping atropine 0.01%, 0.1% and 0.5%. Am J Ophthalmol 2014;157:451–7.e1.
crossref pmid
99. Yam JC, Zhang XJ, Zhang Y, Wang YM, Tang SM, Li FF, et al. Three-year clinical trial of low-concentration atropine for myopia progression (LAMP) study: continued versus washout: phase 3 report. Ophthalmology 2022;129:308–21.
crossref pmid
100. Sankaridurg P, Berntsen DA, Bullimore MA, Cho P, Flitcroft I, Gawne TJ, et al. IMI 2023 digest. Invest Ophthalmol Vis Sci 2023;64:7.
crossref pmid pmc
101. Chung K, Mohidin N, O'Leary DJ. Undercorrection of myopia enhances rather than inhibits myopia progression. Vision Res 2002;42:2555–9.
crossref pmid
102. Wildsoet CF, Chia A, Cho P, Guggenheim JA, Polling JR, Read S, et al. IMI - interventions myopia institute: interventions for controlling myopia onset and progression report. Invest Ophthalmol Vis Sci 2019;60:M106–31.
crossref pmid
103. Li SY, Li SM, Zhou YH, Liu LR, Li H, Kang MT, et al. Effect of undercorrection on myopia progression in 12-year-old children. Graefes Arch Clin Exp Ophthalmol 2015;253:1363–8.
crossref pmid pdf
104. Marsh-Tootle WL, Dong LM, Hyman L, Gwiazda J, Weise KK, Dias L, et al. Myopia progression in children wearing spectacles vs. switching to contact lenses. Optom Vis Sci 2009;86:741–7.
crossref pmid pmc
105. Katz J, Schein OD, Levy B, Cruiscullo T, Saw SM, Rajan U, et al. A randomized trial of rigid gas permeable contact lenses to reduce progression of children's myopia. Am J Ophthalmol 2003;136:82–90.
crossref pmid
106. McBrien NA, Stell WK, Carr B. How does atropine exert its anti-myopia effects? Ophthalmic Physiol Opt 2013;33:373–8.
crossref pmid
107. Upadhyay A, Beuerman RW. Biological mechanisms of atropine control of myopia. Eye Contact Lens 2020;46:129–35.
crossref pmid pmc
108. Metlapally R, Wildsoet CF. Scleral mechanisms underlying ocular growth and myopia. Prog Mol Biol Transl Sci 2015;134:241–8.
crossref pmid pmc
109. Gallego P, Martínez-García C, Pérez-Merino P, Ibares-Frías L, Mayo-Iscar A, Merayo-Lloves J. Scleral changes induced by atropine in chicks as an experimental model of myopia. Ophthalmic Physiol Opt 2012;32:478–84.
crossref pmid
110. Barathi VA, Beuerman RW. Molecular mechanisms of muscarinic receptors in mouse scleral fibroblasts: prior to and after induction of experimental myopia with atropine treatment. Mol Vis 2011;17:680–92.
pmid pmc
111. Barathi VA, Weon SR, Beuerman RW. Expression of muscarinic receptors in human and mouse sclera and their role in the regulation of scleral fibroblasts proliferation. Mol Vis 2009;15:1277–93.
pmid pmc
112. Feldkaemper M, Schaeffel F. An updated view on the role of dopamine in myopia. Exp Eye Res 2013;114:106–19.
crossref pmid
113. Nebbioso M, Plateroti AM, Pucci B, Pescosolido N. Role of the dopaminergic system in the development of myopia in children and adolescents. J Child Neurol 2014;29:1739–46.
crossref pmid pdf
114. Chia A, Chua WH, Cheung YB, Wong WL, Lingham A, Fong A, et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (atropine for the treatment of myopia 2). Ophthalmology 2012;119:347–54.
crossref pmid
115. Yam JC, Jiang Y, Tang SM, Law AKP, Chan JJ, Wong E, et al. Low-concentration atropine for myopia progression (LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control. Ophthalmology 2019;126:113–24.
pmid
116. Yam JC, Li FF, Zhang X, Tang SM, Yip BHK, Kam KW, et al. Two-year clinical trial of the low-concentration atropine for myopia progression (LAMP) study: phase 2 report. Ophthalmology 2020;127:910–9.
crossref pmid
117. Zhang XJ, Zhang Y, Yip BHK, Kam KW, Tang F, Ling X, et al. Five-year clinical trial of the low-concentration atropine for myopia progression (LAMP) study: phase 4 report. Ophthalmology 2024;131:1011–20.
crossref pmid
118. Pineles SL, Kraker RT, VanderVeen DK, Hutchinson AK, Galvin JA, Wilson LB, et al. Atropine for the prevention of myopia progression in children: a report by the American Academy of Ophthalmology. Ophthalmology 2017;124:1857–66.
crossref pmid
119. Loughman J, Flitcroft DI. The acceptability and visual impact of 0.01% atropine in a Caucasian population. Br J Ophthalmol 2016;100:1525–9.
crossref pmid
120. Smith LG. Uses and adverse effects of topical administration of atropine. Ophthalmic Physiol Opt 1988;8:101.
crossref pmid
121. Wakayama A, Nishina S, Miki A, Utsumi T, Sugasawa J, Hayashi T, et al. Incidence of side effects of topical atropine sulfate and cyclopentolate hydrochloride for cycloplegia in Japanese children: a multicenter study. Jpn J Ophthalmol 2018;62:531–6.
crossref pmid pdf
122. Foreman J, Salim AT, Praveen A, Fonseka D, Ting DSW, Guang He M, et al. Association between digital smart device use and myopia: a systematic review and meta-analysis. Lancet Digit Health 2021;3:e806–18.
crossref pmid
123. Huang HM, Chang DS, Wu PC. The association between near work activities and myopia in children-a systematic review and meta-analysis. PLoS One 2015;10:e0140419.
crossref pmid pmc
124. Wen L, Cao Y, Cheng Q, Li X, Pan L, Li L, et al. Objectively measured near work, outdoor exposure and myopia in children. Br J Ophthalmol 2020;104:1542–7.
crossref pmid pmc
125. Rose KA, Morgan IG, Ip J, Kifley A, Huynh S, Smith W, et al. Outdoor activity reduces the prevalence of myopia in children. Ophthalmology 2008;115:1279–85.
crossref pmid
126. Ngo CS, Pan CW, Finkelstein EA, Lee CF, Wong IB, Ong J, et al. A cluster randomised controlled trial evaluating an incentive-based outdoor physical activity programme to increase outdoor time and prevent myopia in children. Ophthalmic Physiol Opt 2014;34:362–8.
crossref pmid
127. Wu PC, Tsai CL, Wu HL, Yang YH, Kuo HK. Outdoor activity during class recess reduces myopia onset and progression in school children. Ophthalmology 2013;120:1080–5.
crossref pmid
128. Hu Y, Zhao F, Ding X, Zhang S, Li Z, Guo Y, et al. Rates of myopia development in young Chinese schoolchildren during the outbreak of COVID-19. JAMA Ophthalmol 2021;139:1115–21.
crossref pmid pmc
129. Ma M, Xiong S, Zhao S, Zheng Z, Sun T, Li C. COVID-19 home quarantine accelerated the progression of myopia in children aged 7 to 12 years in China. Invest Ophthalmol Vis Sci 2021;62:37.
crossref pmid pmc
130. Liu L, Li R, Huang D, Lin X, Zhu H, Wang Y, et al. Prediction of premyopia and myopia in Chinese preschool children: a longitudinal cohort. BMC Ophthalmol 2021;21:283.
crossref pmid pmc pdf
131. Chen Y, Tan C, Foo LL, He S, Zhang J, Bulloch G, et al. Development and validation of a model to predict who will develop myopia in the following year as a criterion to define premyopia. Asia Pac J Ophthalmol (Phila) 2023;12:38–43.
crossref pmid
132. Fang PC, Chung MY, Yu HJ, Wu PC. Prevention of myopia onset with 0.025% atropine in premyopic children. J Ocul Pharmacol Ther 2010;26:341–5.
crossref pmid
133. He X, Sankaridurg P, Wang J, Chen J, Naduvilath T, He M, et al. Time outdoors in reducing myopia: a school-based cluster randomized trial with objective monitoring of outdoor time and light intensity. Ophthalmology 2022;129:1245–54.
pmid
134. Zhang W, Yang F, Chen S, Shi T. Peripheral and posterior pole retinal changes in highly myopic Chinese children and adolescents : retinal changes in Chinese children and adolescents. BMC Ophthalmol 2024;24:65.
pmid pmc
135. Li Y, Zheng F, Foo LL, Wong QY, Ting D, Hoang QV, et al. Advances in OCT imaging in myopia and pathologic myopia. Diagnostics (Basel) 2022;12:1418.
crossref pmid pmc
136. Matalia J, Anegondi NS, Veeboy L, Roy AS. Age and myopia associated optical coherence tomography of retina and choroid in pediatric eyes. Indian J Ophthalmol 2018;66:77–82.
crossref pmid pmc
137. Abdellah MM, Amer AA, Eldaly ZH, Anber MA. Optical coherence tomography angiography of the macula of high myopia in children and adolescents. Int J Retina Vitreous 2024;10:17.
crossref pmid pmc pdf
METRICS Graph View
  • 1 Crossref
  •  0 Scopus
  • 3,290 View
  • 190 Download